Veeva Systems Stock Declines Slightly
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy VEEV?
Source: NASDAQ.COM
- Stock Performance: Veeva Systems (VEEV) closed at $172.52, down 1.21% from the previous day, underperforming the S&P 500's gain of 0.08%, indicating market caution regarding its future performance.
- Monthly Decline: The stock has dropped 10.7% over the past month, significantly worse than the Medical sector's decline of 6.98% and the S&P 500's 1.74% drop, reflecting relative weakness in the company's market position.
- Earnings Expectations: Analysts predict Veeva's upcoming earnings report will show an EPS of $2.12, a 7.61% increase year-over-year, with revenue expected at $857.33 million, reflecting a 12.95% rise, indicating potential for revenue growth.
- Analyst Ratings: Currently rated #2 (Buy) by Zacks, Veeva has seen a 0.17% increase in EPS estimates over the past month, suggesting analysts maintain an optimistic outlook on the company's profitability, despite its forward P/E ratio of 19.91 being in line with the industry average.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VEEV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VEEV
Wall Street analysts forecast VEEV stock price to rise
23 Analyst Rating
16 Buy
6 Hold
1 Sell
Moderate Buy
Current: 174.640
Low
222.00
Averages
317.10
High
380.00
Current: 174.640
Low
222.00
Averages
317.10
High
380.00
About VEEV
Veeva Systems Inc. is a provider of cloud solutions for the global life sciences industry. It offers span cloud software, data and business consulting and is designed to meet the needs of its customers and strategic business functions from research and development (R&D) through commercialization. Its product categories include Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud and Veeva Data Cloud. Veeva Development Cloud includes application suites for the clinical, regulatory, and safety functions of life sciences companies, all built on its Veeva Vault platform. Veeva Quality Cloud unifies applications, processes and partners across content management, training, quality management, assurance and control lab solutions on the Veeva Vault platform. Veeva Commercial Cloud is a product category comprised of software and analytics solutions. It owns Ostro, a brand engagement platform for life sciences that gives an artificial intelligence (AI)-driven chat experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Veeva Systems Stock Declines Slightly
- Stock Performance: Veeva Systems (VEEV) closed at $172.52, down 1.21% from the previous day, underperforming the S&P 500's gain of 0.08%, indicating market caution regarding its future performance.
- Monthly Decline: The stock has dropped 10.7% over the past month, significantly worse than the Medical sector's decline of 6.98% and the S&P 500's 1.74% drop, reflecting relative weakness in the company's market position.
- Earnings Expectations: Analysts predict Veeva's upcoming earnings report will show an EPS of $2.12, a 7.61% increase year-over-year, with revenue expected at $857.33 million, reflecting a 12.95% rise, indicating potential for revenue growth.
- Analyst Ratings: Currently rated #2 (Buy) by Zacks, Veeva has seen a 0.17% increase in EPS estimates over the past month, suggesting analysts maintain an optimistic outlook on the company's profitability, despite its forward P/E ratio of 19.91 being in line with the industry average.
See More
Veeva Systems Faces Challenges Yet Remains Attractive for Investors
- Market Share Concerns: Veeva Systems' stock has dropped 37% over the past six months, raising investor fears about increased competition eroding its market share; however, the current stock price is still considered attractive for long-term investment.
- Strong Customer Base: The company boasts 15 out of the top 20 biopharma companies as clients, demonstrating its robust market position in the life sciences sector, which significantly reduces the risk of customer attrition due to high switching costs.
- AI Investment Potential: Veeva has launched the Veeva AI tool aimed at enhancing productivity by automating tasks such as clinical data review and regulatory compliance, with plans to introduce more AI-driven tools to further expand its market share.
- Significant Market Opportunity: With a total addressable market exceeding $20 billion compared to its trailing 12-month revenue of $3.2 billion, Veeva Systems has substantial growth potential, and its current forward P/E ratio is near multi-year lows, indicating strong investment value.
See More
Veeva Systems: AI-Driven Market Opportunities
- Market Share Challenges: Veeva Systems' stock has declined by 37% over the past six months due to investor concerns about increasing competition; however, the company's long-term outlook remains strong, making the current stock price an attractive buy opportunity.
- Customer Base Expansion: Veeva Systems continues to attract new clients, boasting 15 of the top 20 biopharma companies as customers, which not only strengthens its market position but also lays the groundwork for future revenue growth.
- AI Investment Potential: The company has launched Veeva AI, an intelligent tool designed to enhance productivity by automating tasks such as clinical data review and ensuring compliance, which is expected to further drive market share growth.
- Significant Market Space: Veeva Systems estimates a total addressable market of over $20 billion, while its trailing twelve-month revenue stands at $3.2 billion, indicating substantial growth potential; combined with its current low price-to-earnings ratio, the company is poised for significant returns over the next five years.
See More
Veeva Systems' Market Prospects and Challenges
- Market Growth Potential: Since its IPO in 2013, Veeva Systems has achieved a compound annual growth rate of 13.6%, and despite facing significant competition, the demand for its cloud solutions in the life sciences sector is expected to continue growing, particularly with the aging global population and increasing consumer spending.
- Customer Base Advantage: Veeva's clientele includes 15 of the top 20 biopharma companies, and the high switching costs associated with its services enhance its competitive edge and market position, as clients rely heavily on its platform for critical operations.
- Market Opportunity Assessment: Veeva Systems estimates its current total addressable market at approximately $20 billion, and while revenue growth has slowed, the company still sees ample opportunities for strong revenue and profit growth over the next five years, especially within the life sciences sector.
- Investment Return Potential: To turn a $70,000 investment into $2 million over 30 years, Veeva would need to achieve an annual compound growth rate of 11.82%, which is slightly lower than its past performance but remains attractive given its market leadership and competitive advantages.
See More
Veeva Systems Faces Competitive Challenges Amid Strong Growth
- Market Growth Potential: Since its IPO in 2013, Veeva Systems has achieved a compound annual growth rate of 13.6%, and despite facing competitive pressures, the demand in the life sciences sector is expected to grow, benefiting from an aging population and increased consumer spending.
- Strong Customer Base: Veeva serves 15 of the top 20 biopharma companies, and its clients' reliance on its services for critical activities like clinical trial data management and compliance provides a robust competitive edge.
- Broad Market Opportunities: With a current total addressable market of approximately $20 billion, Veeva Systems has the potential for strong revenue and profit growth over the next five years, especially as it expands into new markets like cosmetics and consumer packaged goods.
- Investment Return Potential: To turn a $70,000 investment into $2 million over 30 years, Veeva would need to achieve an 11.82% compound annual growth rate, which, while slightly lower than its historical performance, remains competitive in the current market landscape.
See More
Veeva Systems: Analyzing Future Growth Potential
- Market Growth Potential: Since its IPO in 2013, Veeva Systems has achieved a compound annual growth rate of 13.6%, and despite facing competitive pressures, the demand in the life sciences sector is expected to continue growing, particularly with the aging population and increasing consumer spending.
- Customer Base Advantage: Veeva serves 15 of the top 20 biopharma companies, and the high switching costs for clients relying on its services enhance its market position and competitive edge in the industry.
- Market Opportunity Assessment: Veeva Systems estimates its current total addressable market at approximately $20 billion, and while revenue growth has slowed, the company still has opportunities for strong revenue and profit growth over the next five years, especially as it expands into new markets.
- Investment Return Potential: To turn a $70,000 investment into $2 million over 30 years, Veeva would need to achieve an 11.82% compound annual growth rate, which, while slightly lower than its past performance, positions it as a potential long-term investment given its leadership in core markets and competitive advantages.
See More
Veeva Systems Stock Declines Slightly
- Stock Performance: Veeva Systems (VEEV) closed at $172.52, down 1.21% from the previous day, underperforming the S&P 500's gain of 0.08%, indicating market caution regarding its future performance.
- Monthly Decline: The stock has dropped 10.7% over the past month, significantly worse than the Medical sector's decline of 6.98% and the S&P 500's 1.74% drop, reflecting relative weakness in the company's market position.
- Earnings Expectations: Analysts predict Veeva's upcoming earnings report will show an EPS of $2.12, a 7.61% increase year-over-year, with revenue expected at $857.33 million, reflecting a 12.95% rise, indicating potential for revenue growth.
- Analyst Ratings: Currently rated #2 (Buy) by Zacks, Veeva has seen a 0.17% increase in EPS estimates over the past month, suggesting analysts maintain an optimistic outlook on the company's profitability, despite its forward P/E ratio of 19.91 being in line with the industry average.
See More
Veeva Systems Faces Challenges Yet Remains Attractive for Investors
- Market Share Concerns: Veeva Systems' stock has dropped 37% over the past six months, raising investor fears about increased competition eroding its market share; however, the current stock price is still considered attractive for long-term investment.
- Strong Customer Base: The company boasts 15 out of the top 20 biopharma companies as clients, demonstrating its robust market position in the life sciences sector, which significantly reduces the risk of customer attrition due to high switching costs.
- AI Investment Potential: Veeva has launched the Veeva AI tool aimed at enhancing productivity by automating tasks such as clinical data review and regulatory compliance, with plans to introduce more AI-driven tools to further expand its market share.
- Significant Market Opportunity: With a total addressable market exceeding $20 billion compared to its trailing 12-month revenue of $3.2 billion, Veeva Systems has substantial growth potential, and its current forward P/E ratio is near multi-year lows, indicating strong investment value.
See More
Veeva Systems: AI-Driven Market Opportunities
- Market Share Challenges: Veeva Systems' stock has declined by 37% over the past six months due to investor concerns about increasing competition; however, the company's long-term outlook remains strong, making the current stock price an attractive buy opportunity.
- Customer Base Expansion: Veeva Systems continues to attract new clients, boasting 15 of the top 20 biopharma companies as customers, which not only strengthens its market position but also lays the groundwork for future revenue growth.
- AI Investment Potential: The company has launched Veeva AI, an intelligent tool designed to enhance productivity by automating tasks such as clinical data review and ensuring compliance, which is expected to further drive market share growth.
- Significant Market Space: Veeva Systems estimates a total addressable market of over $20 billion, while its trailing twelve-month revenue stands at $3.2 billion, indicating substantial growth potential; combined with its current low price-to-earnings ratio, the company is poised for significant returns over the next five years.
See More
Veeva Systems' Market Prospects and Challenges
- Market Growth Potential: Since its IPO in 2013, Veeva Systems has achieved a compound annual growth rate of 13.6%, and despite facing significant competition, the demand for its cloud solutions in the life sciences sector is expected to continue growing, particularly with the aging global population and increasing consumer spending.
- Customer Base Advantage: Veeva's clientele includes 15 of the top 20 biopharma companies, and the high switching costs associated with its services enhance its competitive edge and market position, as clients rely heavily on its platform for critical operations.
- Market Opportunity Assessment: Veeva Systems estimates its current total addressable market at approximately $20 billion, and while revenue growth has slowed, the company still sees ample opportunities for strong revenue and profit growth over the next five years, especially within the life sciences sector.
- Investment Return Potential: To turn a $70,000 investment into $2 million over 30 years, Veeva would need to achieve an annual compound growth rate of 11.82%, which is slightly lower than its past performance but remains attractive given its market leadership and competitive advantages.
See More
Veeva Systems Faces Competitive Challenges Amid Strong Growth
- Market Growth Potential: Since its IPO in 2013, Veeva Systems has achieved a compound annual growth rate of 13.6%, and despite facing competitive pressures, the demand in the life sciences sector is expected to grow, benefiting from an aging population and increased consumer spending.
- Strong Customer Base: Veeva serves 15 of the top 20 biopharma companies, and its clients' reliance on its services for critical activities like clinical trial data management and compliance provides a robust competitive edge.
- Broad Market Opportunities: With a current total addressable market of approximately $20 billion, Veeva Systems has the potential for strong revenue and profit growth over the next five years, especially as it expands into new markets like cosmetics and consumer packaged goods.
- Investment Return Potential: To turn a $70,000 investment into $2 million over 30 years, Veeva would need to achieve an 11.82% compound annual growth rate, which, while slightly lower than its historical performance, remains competitive in the current market landscape.
See More
Veeva Systems: Analyzing Future Growth Potential
- Market Growth Potential: Since its IPO in 2013, Veeva Systems has achieved a compound annual growth rate of 13.6%, and despite facing competitive pressures, the demand in the life sciences sector is expected to continue growing, particularly with the aging population and increasing consumer spending.
- Customer Base Advantage: Veeva serves 15 of the top 20 biopharma companies, and the high switching costs for clients relying on its services enhance its market position and competitive edge in the industry.
- Market Opportunity Assessment: Veeva Systems estimates its current total addressable market at approximately $20 billion, and while revenue growth has slowed, the company still has opportunities for strong revenue and profit growth over the next five years, especially as it expands into new markets.
- Investment Return Potential: To turn a $70,000 investment into $2 million over 30 years, Veeva would need to achieve an 11.82% compound annual growth rate, which, while slightly lower than its past performance, positions it as a potential long-term investment given its leadership in core markets and competitive advantages.
See More
